Hassan R. K.
- Country
- Belgium
- Department
- Oncology
Research Overview
Data & Insights
Has run more than one trial at 0 of 22 partner sites.
Specializations
Hormone Receptor–Positive Breast Cancer
Focus on endocrine‑based strategies for HR+/HER2- breast cancer.
- Adjuvant CDK4/6 inhibition
- PIK3CA‑mutated disease management
- ctDNA‑guided therapy
Therapeutic aim is to prolong disease‑free survival.
Hematologic Oncology
Investigates targeted agents for multiple myeloma and acute leukemias.
- B‑cell lymphoma immunotherapy
- NPM1‑mutated AML regimens
- KIR3DL2‑positive T‑cell lymphoma therapies
Emphasis on improving progression‑free outcomes.
Metastatic Renal Cell Carcinoma
Evaluates combination immunotherapy for metastatic renal cell carcinoma.
- PDL1‑stratified ICI‑TKI regimens
- Nivolumab‑ipilimumab sequencing strategies
Goal is to extend overall survival.
Gynecologic Oncology
Develops maintenance strategies for endometrial cancer.
- Selective nuclear export inhibition as maintenance
- Placebo‑controlled maintenance therapy
Target is to delay disease recurrence.
Prostate Cancer
Studies metastasis‑directed and hormonal approaches for high‑risk prostate cancer.
- Short‑term androgen deprivation therapy
- Metastasis‑directed radiotherapy
Focus on prolonging metastasis‑free survival.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.